Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Kumar on the Safety and Efficacy of Venetoclax in Myeloma

January 24th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

Dr. Landgren on Daratumumab Triplet in Relapsed Myeloma

January 19th 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.

Expert Touts Value of Lenalidomide Maintenance in Myeloma

January 19th 2017

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Dr. Jackson on Benefits of Maintenance Therapy for Myeloma

January 18th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Immunotherapy for Myeloma & Final Thoughts on Myeloma Research at ASH 2016

January 17th 2017

Emerging Therapies for Myeloma

January 17th 2017

Choosing Triplet Therapy at Myeloma Relapse

January 17th 2017

Relapsed/Refractory Myeloma: Daratumumab-Containing Triplets

January 17th 2017

Elderly Patients With Myeloma

January 17th 2017

Consolidation/Maintenance Therapy in Myeloma

January 17th 2017

Transplant in Multiple Myeloma

January 17th 2017

Which Proteasome Inhibitor for Upfront Treatment of Myeloma?

January 17th 2017

New Data for Newly Diagnosed Myeloma

January 17th 2017

Treating High-Risk Asymptomatic Myeloma

January 17th 2017

Classifying Indolent Versus Active Myeloma

January 17th 2017

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

January 17th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the challenges facing the field of multiple myeloma.

Dr. Usmani on Importance of CASTOR/POLLUX Trials in Myeloma

January 14th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the importance of the CASTOR and POLLUX trials for the treatment of patients with multiple myeloma.

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Landgren on Questions After POLLUX and CASTOR Studies in Myeloma

January 6th 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses unanswered questions following the results of the phase III POLLUX and CASTOR studies, which explored the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, respectively.

Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers

January 2nd 2017

The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.